Market closedNon-fractional
iRadimed/IRMD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About iRadimed
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.
Ticker
IRMD
Sector
Healthcare
Trading on
NASDAQ
Industry
Health Care Equipment and Supplies
Headquarters
Winter Springs, United States
Employees
148
Website
www.iradimed.com
iRadimed Metrics
BasicAdvanced
$598M
Market cap
33.76
P/E ratio
$1.40
EPS
0.87
Beta
$0.15
Dividend rate
0.32%
Dividend yield
Price and volume
Market cap
$598M
Beta
0.87
Dividend rate
$0.15
Financial strength
Current ratio
9.438
Quick ratio
5.925
Long term debt to equity
1.996
Total debt to equity
2.546
Dividend payout ratio (TTM)
44.50%
Management effectiveness
Return on assets (TTM)
15.87%
Return on equity (TTM)
25.52%
Valuation
Price to earnings (TTM)
33.757
Price to revenue (TTM)
8.81
Price to book
7.66
Price to tangible book (TTM)
7.66
Price to free cash flow (TTM)
55.352
Dividend yield (TTM)
0.32%
Growth
Revenue change (TTM)
19.87%
Earnings per share change (TTM)
28.40%
3-year revenue growth (CAGR)
28.01%
3-year earnings per share growth (CAGR)
158.87%
What the Analysts think about iRadimed
Analyst Ratings
Majority rating from 2 analysts.
iRadimed Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$18M
0.57%
Net income
$4.1M
-8.89%
Profit margin
23.42%
-9.44%
iRadimed Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.36
$0.43
$0.39
$0.36
-
Expected
$0.31
$0.36
$0.40
$0.34
$0.37
Surprise
16.13%
18.35%
-1.68%
7.46%
-
iRadimed News
AllArticlesVideos
IRADIMED CORPORATION to Hold 2024 Second Quarter Financial Results Conference Call on August 1st
GlobeNewsWire·2 days ago
IRADIMED CORPORATION Announces Uplisting to The Nasdaq Global Market
GlobeNewsWire·2 months ago
IRADIMED CORPORATION (IRMD) Q1 2024 Earnings Call Transcript
Seeking Alpha·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for iRadimed stock?
iRadimed (IRMD) has a market cap of $598M as of July 27, 2024.
What is the P/E ratio for iRadimed stock?
The price to earnings (P/E) ratio for iRadimed (IRMD) stock is 33.76 as of July 27, 2024.
Does iRadimed stock pay dividends?
Yes, the iRadimed (IRMD) stock pays dividends to shareholders. As of July 27, 2024, the dividend rate is $0.15 and the yield is 0.32%. iRadimed has a payout ratio of 44.5% on a trailing twelve-month basis.
When is the next iRadimed dividend payment date?
The next iRadimed (IRMD) dividend payment date is unconfirmed.
What is the beta indicator for iRadimed?
iRadimed (IRMD) has a beta rating of 0.87. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell iRadimed stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.